Efficacy of avasimibe in peripheral arterial disease

$0M01FY2000RRNIH

Oregon Health And Science University, Portland OR

Investigators

Linked publications & trials

Paper 37914632 Paper 33002231 Paper 32603605 Paper 32176647 Paper 31505070 Paper 31404238 Paper 30684471 Paper 30012837 Paper 28236716 Paper 27870939 Paper 27669423 Paper 26957355 Paper 26812281 Paper 26807428 Paper 26416619 Paper 25328912 Paper 25122491 Paper 24911216 Paper 24077434 Paper 23985292 Paper 23891537 Paper 23538569 Paper 23416849 Paper 23208029 Paper 23140884 Paper 23102124 Paper 22669363 Paper 22569476 Paper 22514099 Paper 21803872 Paper 21728433 Paper 21494919 Paper 21466949 Paper 21367394 Paper 21297427 Paper 21234692 Paper 21185275 Paper 21128149 Paper 21035033 Paper 20926574 Paper 20876818 Paper 20803391 Paper 20801706 Paper 20643702 Paper 20630734 Paper 20624243 Paper 20604695 Paper 20522090 Paper 20494414 Paper 20466110 Paper 20430137 Paper 20388787 Paper 20231619 Paper 20227053 Paper 20215591 Paper 20206848 Paper 20201937 Paper 20167187 Paper 20159182 Paper 20143429 Paper 20140523 Paper 20044903 Paper 20031601 Paper 19866475 Paper 19850743 Paper 19838935 Paper 19784398 Paper 19679306 Paper 19631786 Paper 19597134 Paper 19509608 Paper 19506209 Paper 19454588 Paper 19412328 Paper 19360491 Paper 19327589 Paper 19196720 Paper 19171833 Paper 19101685 Paper 19081833 Paper 19037811 Paper 19014790 Paper 18981035 Paper 18660445 Paper 18632003 Paper 18585512 Paper 18525292 Paper 18521501 Paper 18502162 Paper 18450845 Paper 18419322 Paper 18395206 Paper 18334754 Paper 18317425 Paper 18282317 Paper 18272671 Paper 18240245 Paper 18208859 Paper 18206696 Paper 18165936

Abstract

The incidence of symptomatic Peripheral Aterial Disease (PAD) increases with age and is more prevalent in men than women. Risk factors for PAD include smoking, diabetes, and high blood pressure. PAD is caused by atherosclerosis with the main symptom being intermittent claudication (IC). IC describes the pain experienced in the calves, thighs, and buttocks when persons walk. The purpose of this study is to see if a new medication, avasimibe, will increase the distance a person can walk before having to stop because of pain. The study will last for 52 weeks.

View original record on NIH RePORTER →